{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:55:40Z","timestamp":1784300140741,"version":"3.55.0"},"reference-count":26,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,1,7]]},"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum \u03b2-lactamase-producing\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      (ESBL-EC) is imperative. Although fosfomycin was discovered more than 40\u2005years ago, it was not investigated in accordance with current standards and so is not used in clinical practice except in desperate situations. It is one of the so-called neglected antibiotics of high potential interest for the future.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The main objective of this project is to demonstrate the clinical non-inferiority of intravenous fosfomycin with regard to meropenem for treating bacteraemic urinary tract infections (UTI) caused by ESBL-EC. This is a \u2018real practice\u2019 multicentre, open-label, phase III randomised controlled trial, designed to compare the clinical and microbiological efficacy, and safety of intravenous fosfomycin (4\u2005g\/6\u2005h) and meropenem (1\u2005g\/8\u2005h) as targeted therapy for this infection; a change to oral therapy is permitted after 5\u2005days in both arms, in accordance with predetermined options. The study design follows the latest recommendations for designing trials investigating new options for multidrug-resistant bacteria. Secondary objectives include the study of fosfomycin concentrations in plasma and the impact of both drugs on intestinal colonisation by multidrug-resistant Gram-negative bacilli.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was obtained from the Andalusian Coordinating Institutional Review Board (IRB) for Biomedical Research (Referral Ethics Committee), which obtained approval from the local ethics committees at all participating sites in Spain (22 sites). Data will be presented at international conferences and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This project is proposed as an initial step in the investigation of an orphan antimicrobial of low cost with high potential as a therapeutic alternative in common infections such as UTI in selected patients. These results may have a major impact on the use of antibiotics and the development of new projects with this drug, whether as monotherapy or combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT02142751. EudraCT no: 2013-002922-21. Protocol V.1.1 dated 14 March 2014.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2014-007363","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T09:58:27Z","timestamp":1427882307000},"page":"e007363","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":55,"title":["Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing\n                    <i>Escherichia coli<\/i>\n                    (FOREST): study protocol for an investigator-driven randomised controlled trial"],"prefix":"10.1136","volume":"5","author":[{"given":"Clara","family":"Rosso-Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Unidad de ensayos cl\u00ednicos, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"},{"name":"Farmacolog\u00eda Cl\u00ednica, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Sojo-Dorado","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica Intercentros de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Barriga","sequence":"additional","affiliation":[{"name":"Unidad de ensayos cl\u00ednicos, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Lav\u00edn-Alconero","sequence":"additional","affiliation":[{"name":"Unidad de ensayos cl\u00ednicos, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaira","family":"Palacios","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica Intercentros de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Roc\u00edo, Seville, Spain"},{"name":"Unidad Cl\u00ednica de Medicina Interna, Hospital Universitario Virgen Macarena, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica Intercentros de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Merino","sequence":"additional","affiliation":[{"name":"Unidad de Farmacia, Hospital Universitario Virgen Macarena, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Camean","sequence":"additional","affiliation":[{"name":"Unidad de Farmacia, Hospital Universitario Virgen Macarena, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Pascual","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica Intercentros de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Roc\u00edo, Seville, Spain"},{"name":"Departamento de Microbiolog\u00eda, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Rodr\u00edguez-Ba\u00f1o","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica Intercentros de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Roc\u00edo, Seville, Spain"},{"name":"Departamento de Medicina, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the FOREST Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,3,31]]},"reference":[{"key":"2025121408405493000_5.3.e007363.1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit181"},{"key":"2025121408405493000_5.3.e007363.2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2217\/fmb.14.35","article-title":"Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies","volume":"9","author":"Bettiol","year":"2014","journal-title":"Future Microbiol"},{"key":"2025121408405493000_5.3.e007363.3","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.5.671"},{"key":"2025121408405493000_5.3.e007363.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70318-9"},{"key":"2025121408405493000_5.3.e007363.5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks065"},{"key":"2025121408405493000_5.3.e007363.6","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm193"},{"key":"2025121408405493000_5.3.e007363.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.10.019"},{"key":"2025121408405493000_5.3.e007363.8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.368-370.2006"},{"key":"2025121408405493000_5.3.e007363.9","unstructured":"Spanish Agency of Medicines and Medical Devices. Disodium fosfomycin (data sheet). http:\/\/www.aemps.gob.es\/cima\/pdfs\/es\/ft\/54165\/FT_54165 (accessed 11 Nov 2014)."},{"key":"2025121408405493000_5.3.e007363.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70325-1"},{"key":"2025121408405493000_5.3.e007363.11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025121408405493000_5.3.e007363.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586"},{"key":"2025121408405493000_5.3.e007363.13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir838"},{"key":"2025121408405493000_5.3.e007363.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70293-1"},{"key":"2025121408405493000_5.3.e007363.15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis688"},{"key":"2025121408405493000_5.3.e007363.16","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq346"},{"key":"2025121408405493000_5.3.e007363.17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/dkr466","article-title":"Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens","volume":"67","author":"Karageorgopoulos","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025121408405493000_5.3.e007363.18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00462-11"},{"key":"2025121408405493000_5.3.e007363.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.08.013"},{"key":"2025121408405493000_5.3.e007363.20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq070"},{"key":"2025121408405493000_5.3.e007363.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.05.018"},{"key":"2025121408405493000_5.3.e007363.22","unstructured":"FDA. Complicated urinary tract infections: developing drugs for treatment. Draft guidance. February 2012."},{"key":"2025121408405493000_5.3.e007363.23","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.1.86"},{"key":"2025121408405493000_5.3.e007363.24","unstructured":"Ertapenem label information. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000389\/WC500033921.pdf"},{"key":"2025121408405493000_5.3.e007363.25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.17.1897"},{"key":"2025121408405493000_5.3.e007363.26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir790"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-007363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:41:03Z","timestamp":1765730463000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-007363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,31]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1136\/bmjopen-2014-007363"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-007363","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}